USD | |
---|---|
Revenue (FY, 2017) | 327 k |
Net income (FY, 2017) | (95.2 m) |
EBIT (FY, 2017) | (96 m) |
Market capitalization (20-Apr-2018) | 950.7 m |
Cash (31-Dec-2017) | 26.6 m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.5 m | 3 m | 2.2 m | 627 k | 1.6 m | 1.2 m | 942 k | 2.6 m | 162 k | 148 k | 105 k | |
General and administrative expense | 5.8 m | 4.2 m | 4.1 m | 4.1 m | 4.9 m | 5.1 m | 5.5 m | 8.2 m | 9.2 m | 11.8 m | 6.5 m | 5.6 m |
R&D expense | 11.8 m | 13.2 m | 23.6 m | 28.1 m | 22.2 m | 19.7 m | 24.1 m | 20.1 m | 22.8 m | 23.2 m | 16.3 m | 14.8 m |
Operating expense total | 18.5 m | 17.5 m | 27.9 m | 32.3 m | 27.1 m | 24.8 m | 29.6 m | 28.2 m | 31.9 m | 35 m | 25.6 m | 20.4 m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 12.2 m | 26.8 m | 17 m | 19.7 m | 14.7 m | 36.5 m | 103 m | 38.9 m | 24.8 m | 23 m | 21.5 m | 37.7 m |
Accounts Receivable | 2.2 m | 1.7 m | 1.3 m | 727 k | 909 k | 657 k | 1.2 m | 1.2 m | ||||
Current Assets | 79.8 m | 181.7 m | 160.6 m | 134.9 m | 102 m | 97.9 m | 224.3 m | 170.7 m | 147.1 m | 117.5 m | 89.7 m | 132.2 m |
PP&E | 8.5 m | 8.6 m | 8.8 m | 8.1 m | 7.5 m | 8.9 m | 11.6 m | 15.9 m | 17.4 m | 18.7 m | 16.6 m | 16.8 m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (15.7 m) | (13.8 m) | (24.8 m) | (29.8 m) | (26.2 m) | (23.6 m) | (30.1 m) | (27 m) | (29 m) | (34.7 m) | (25.3 m) |
Accounts Payable | 1.9 m | 5 m | 3.3 m | 2.3 m | 2.4 m | 3.5 m | 4.5 m | 3.8 m | 1.5 m |
USD | Y, 2017 |
---|---|
Revenue/Employee | 1.3 k |
Financial Leverage | 1.1 x |
FY, 2016 | |
---|---|
Patents (foreign) | 260 |
Patents Pending | 40 |
Phase III Trials Products | 1 |
Preclinical Phase Products | 2 |